How big is the Stem Cell Manufacturing Market?

The Stem Cell Manufacturing Market size is expected to reach USD 15.08 billion in 2024 and grow at a CAGR of 12.96% to reach USD 27.74 billion by 2029. Read More

What is the current Stem Cell Manufacturing Market size?

In 2024, the Stem Cell Manufacturing Market size is expected to reach USD 15.08 billion. Read More

Which is the fastest growing region in Stem Cell Manufacturing Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Stem Cell Manufacturing Market?

In 2024, the North America accounts for the largest market share in Stem Cell Manufacturing Market. Read More

What years does this Stem Cell Manufacturing Market cover, and what was the market size in 2023?

In 2023, the Stem Cell Manufacturing Market size was estimated at USD 13.13 billion. The report covers the Stem Cell Manufacturing Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Stem Cell Manufacturing Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Stem Cell Manufacturing Market Share

Q: Who are the key players in Stem Cell Manufacturing Market?

Becton, Dickinson and Company, Lonza Group, Stemcell Technologies, Merck Group and Fujifilm Holdings Corporation (Cellular Dynamics) are the major companies operating in the Stem Cell Manufacturing Market. Read More

Statistics for the 2023 & 2024 Stem Cell Manufacturing market share, created by Mordor Intelligence™ Industry Reports. Stem Cell Manufacturing share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Stem Cell Manufacturing Industry

The stem cell manufacturing market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Becton, Dickinson and Company, Fujifilm Holdings Corporation (Cellular Dynamics), Lonza Group, Stemcell Technologies, Merck Group, Thermo Fisher Scientific, and Pluristem Therapeutics Inc.